
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Maui, Hawaii - Topical anesthetics represent the state-of-the-art for minimizing pain and anxiety in procedures ranging from filler injections and chemical peels to those used in pediatric dermatology, Lawrence F. Eichenfield, M.D., said at the annual Hawaii Dermatology Seminar, sponsored by the Skin Disease Education Foundation.






